Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Patients taking common blood pressure drug show symptoms of celiac disease

Mayo Clinic researchers have discovered an association between a commonly prescribed blood pressure drug, Olmesartan, and severe gastrointestinal issues such as nausea, vomiting, diarrhea, weight loss and electrolyte abnormalities -- symptoms common among those who have celiac disease. The findings are published online today in the medical journal Mayo Clinic Proceedings.

22 Jun 2012

Link between Olmesartan drug and severe GI issues

22 Jun 2012

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson's disease (PD) regimen, significantly improved the duration of the drugs' effectiveness in people with advanced PD, according to research by Mount Sinai School of Medicine.

21 Jun 2012

Age no barrier to disordered eating

Eating disorders are commonly seen as an issue faced by teenagers and young women, but a new study reveals that age is no barrier to disordered eating. In women aged 50 and over, 3.5% report binge eating, nearly 8% report purging, and more than 70% are trying to lose weight.

21 Jun 2012

Imaging vital to localize stroke

Clinical signs and symptoms can rarely distinguish posterior circulation infarction from anterior circulation infarction, say researchers.

19 Jun 2012

Multi-modal approach reduces pain and side effects of medication following joint replacement surgery

Reducing acute post-surgical pain and side effects of medications for patients undergoing knee and hip replacement surgery is the focus of a new multi-modal approach at Greenwich Hospital in Greenwich, Connecticut.

19 Jun 2012

Ginger gum can cure migraine headaches

If you or someone you care about is among the one in 10 Americans who suffer with migraine headaches, recent research may provide some relief.

16 Jun 2012

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Patients with locally advanced pancreatic cancer have a more favorable prognosis after palliative chemoradiotherapy if they have previously been treated with a gemcitabine-based therapy, say Danish researchers.

14 Jun 2012

Targeting noradrenergic system combats gait freezing in Parkinson’s patients

Methylphenidate may be a useful treatment for patients with advanced Parkinson's disease receiving subthalamic nucleus stimulation who experience gait hypokinesia and freezing, show findings from a randomized trial.

14 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Investigational drug slows metastatic breast cancer progression

Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Amgen today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis.

8 Jun 2012

No benefits to polychemotherapy after surgery in gastric cancer

Findings from the ITACA-S trial suggest that a more intensive postoperative chemotherapy regimen does not improve outcomes over a less-intensive regimen after radical resection in patients with gastric cancer.

7 Jun 2012

New nanomedicine cancer treatments promise to reduce severity of side effects

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the current edition of Chemical & Engineering News.

7 Jun 2012

Savient announces results from KRYSTEXXA Phase III trials on gout-related kidney disease

Savient Pharmaceuticals, Inc. announced that new data presented in an oral session at the European League Against Rheumatism (EULAR) 2012 congress showed that patients with refractory chronic gout (RCG) who also suffer from chronic kidney disease (CKD) responded to treatment with KRYSTEXXA (pegloticase) regardless of baseline CKD stage.

7 Jun 2012

Debiopharm announces results from Debio 0932 Phase I study on cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.

7 Jun 2012

Iron and micronutrient-enriched foodstuffs can fight against anaemia

Iron deficiency and the anaemia it can cause are a major public health problem, affecting 2 billion people worldwide: mostly young children and pregnant women in developing countries. Despite decades of research into prevention and treatment, the situation is not improving, and is even deteriorating in some countries. Africa and India have the highest levels of anaemia, with more than 50% of women affected. In India, the illness is thought to cause up to 40% of maternal deaths.

6 Jun 2012

Bayer announces updated data from radium-223 dichloride Phase III trial on CRPC

Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012